MX2022006714A - Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos. - Google Patents
Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.Info
- Publication number
- MX2022006714A MX2022006714A MX2022006714A MX2022006714A MX2022006714A MX 2022006714 A MX2022006714 A MX 2022006714A MX 2022006714 A MX2022006714 A MX 2022006714A MX 2022006714 A MX2022006714 A MX 2022006714A MX 2022006714 A MX2022006714 A MX 2022006714A
- Authority
- MX
- Mexico
- Prior art keywords
- bcma
- multiple myeloma
- antibodies
- bisespecific
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944589P | 2019-12-06 | 2019-12-06 | |
| US202063055085P | 2020-07-22 | 2020-07-22 | |
| US202063057769P | 2020-07-28 | 2020-07-28 | |
| PCT/US2020/063395 WO2021113701A1 (en) | 2019-12-06 | 2020-12-04 | Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006714A true MX2022006714A (es) | 2022-08-08 |
Family
ID=74106148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006714A MX2022006714A (es) | 2019-12-06 | 2020-12-04 | Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11919965B2 (enExample) |
| EP (1) | EP4069373A1 (enExample) |
| JP (2) | JP7693672B2 (enExample) |
| KR (1) | KR20220110510A (enExample) |
| CN (1) | CN114929343B (enExample) |
| AU (1) | AU2020398167A1 (enExample) |
| CA (1) | CA3160352A1 (enExample) |
| IL (1) | IL293288A (enExample) |
| MX (1) | MX2022006714A (enExample) |
| WO (1) | WO2021113701A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| EP4426437A4 (en) * | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| TW202517293A (zh) * | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN117886939B (zh) * | 2023-12-15 | 2024-07-26 | 康众(广东)生物医药有限公司 | 一组抗bcma的纳米抗体及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| TW202611075A (zh) * | 2024-05-13 | 2026-03-16 | 美商再生元醫藥公司 | 以雙特異性BCMAxCD3抗體治療輕鏈類澱粉變性症之方法 |
| WO2026059923A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| WO2026059917A1 (en) * | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR095374A1 (es) * | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| MY195059A (en) * | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| ES2954153T3 (es) * | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| UA126657C2 (uk) * | 2016-02-03 | 2023-01-11 | Емджен Рісерч (Мюнік) Ґмбг | ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font> |
| KR102531251B1 (ko) * | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| KR102520731B1 (ko) * | 2016-09-23 | 2023-04-14 | 리제너론 파아마슈티컬스, 인크. | 항-steap2 항체, 항체-약물 컨쥬게이트, 및 steap2 및 cd3에 결합하는 이중특이적 항원-결합 분자, 및 이의 용도 |
| US11124577B2 (en) * | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) * | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| KR20210143246A (ko) * | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
-
2020
- 2020-12-04 JP JP2022533414A patent/JP7693672B2/ja active Active
- 2020-12-04 WO PCT/US2020/063395 patent/WO2021113701A1/en not_active Ceased
- 2020-12-04 CA CA3160352A patent/CA3160352A1/en active Pending
- 2020-12-04 KR KR1020227021340A patent/KR20220110510A/ko active Pending
- 2020-12-04 EP EP20834037.2A patent/EP4069373A1/en active Pending
- 2020-12-04 MX MX2022006714A patent/MX2022006714A/es unknown
- 2020-12-04 IL IL293288A patent/IL293288A/en unknown
- 2020-12-04 CN CN202080090951.6A patent/CN114929343B/zh active Active
- 2020-12-04 US US17/112,564 patent/US11919965B2/en active Active
- 2020-12-04 AU AU2020398167A patent/AU2020398167A1/en active Pending
-
2024
- 2024-02-01 US US18/429,887 patent/US20250051466A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093006A patent/JP2025131696A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220110510A (ko) | 2022-08-08 |
| CN114929343B (zh) | 2025-03-18 |
| WO2021113701A1 (en) | 2021-06-10 |
| JP2025131696A (ja) | 2025-09-09 |
| EP4069373A1 (en) | 2022-10-12 |
| IL293288A (en) | 2022-07-01 |
| CN114929343A (zh) | 2022-08-19 |
| US20210206865A1 (en) | 2021-07-08 |
| AU2020398167A1 (en) | 2022-07-28 |
| US11919965B2 (en) | 2024-03-05 |
| JP7693672B2 (ja) | 2025-06-17 |
| CA3160352A1 (en) | 2021-06-10 |
| JP2023505218A (ja) | 2023-02-08 |
| US20250051466A1 (en) | 2025-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025005515A (es) | Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos | |
| JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| JOP20200292A1 (ar) | Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| PH12019500550A1 (en) | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates | |
| EA202190315A1 (ru) | Химерные антигенные рецепторы со специфичностью к bcma и их применение | |
| MX2021014193A (es) | Moleculas de enlace biespecificas anti-ror1/anti-cd3. | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
| EA201890785A1 (ru) | Оптимизированные биспецифические анти-cd3 антитела и их применение | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MY204733A (en) | Anti-pd-l1 antibodies and use thereof | |
| MX2024013676A (es) | Anticuerpos triespecificos para cumulo de diferenciacion 3 (cd3)/antigeno de maduracion de celulas b (bcma)/cumulo de diferenciacion (cd38) | |
| EA202192654A1 (ru) | Слитый белок, содержащий анти-мезотелин антитело, анти-cd3 антитело или анти-egfr антитело, биспецифическое или триспецифическое антитело, содержащие его, и их применения | |
| EA202190314A1 (ru) | Биспецифические анти-bcma x анти-cd3 антитела и способы их применения | |
| ZA202108422B (en) | Anti-cd25 for tumour specific cell depletion | |
| MX2024014547A (es) | Anticuerpos anti-bcma | |
| EA202092753A1 (ru) | Биспецифические антитела к bcma/cd3 и gprdc5d/cd3 для применения в лечении рака | |
| TH2101000210A (th) | ไบสเปซิฟิกแอนติ-BCMA x แอนติ-CD3 แอนติบอดี และการใช้แอนติบอดีดังกล่าว | |
| MX2025010217A (es) | Anticuerpos multiespecificos anti-cd3 y metodos de uso | |
| MX2026000164A (es) | Anticuerpos pd-l1xcd28 biespecificos y metodos de uso de los mismos | |
| EA202090303A2 (ru) | Композиции антител для лечения опухолей | |
| EA201991227A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения |